WithdrawnPHASE1, PHASE2NCT02521090

EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma

Studying Gliosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Barbara Ann Karmanos Cancer Institute
Principal Investigator
Sandeep Mittal, MD FRCSC FACS
Barbara Ann Karmanos Cancer Institute
Intervention
EGFRBi-Armed Autologous T Cells(biological)
Eligibility
18 years · All sexes
Timeline
2015

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02521090 on ClinicalTrials.gov

Other trials for Gliosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Gliosarcoma →

← Back to all trials